Eytan M Stein


Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA


  1. Stein E, DiNardo C, Fathi A, Pollyea D, Stone R, Altman J, et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood. 2018;: pubmed publisher
    ..Enasidenib was well-tolerated and induced molecular remissions and hematologic responses in patients with AML for whom prior treatments had failed. The study is registered to https://clinicaltrials.gov as NCT01915498. ..
  2. DiNardo C, Stein E. SOHO State of the Art Update and Next Questions: IDH Therapeutic Targeting in AML. Clin Lymphoma Myeloma Leuk. 2018;18:769-772 pubmed publisher
    ..IDH inhibitors in combination with standard-of-care therapy and other small molecular inhibitors are now being used. ..
  3. Stein E, Garcia Manero G, Rizzieri D, Tibes R, Berdeja J, Savona M, et al. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. Blood. 2018;: pubmed publisher
    ..This clinical trial is registered at www.clinicaltrials.gov as no. NCT01684150. ..
  4. Intlekofer A, Shih A, Wang B, Nazir A, Rustenburg A, Albanese S, et al. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. Nature. 2018;559:125-129 pubmed publisher
    ..Our observations uncover a mechanism of acquired resistance to a targeted therapy and underscore the importance of 2HG production in the pathogenesis of IDH-mutant malignancies. ..
  5. Stein E. Molecular Pathways: IDH2 Mutations-Co-opting Cellular Metabolism for Malignant Transformation. Clin Cancer Res. 2016;22:16-9 pubmed publisher
    ..AG-221, a small-molecule inhibitor of mutant IDH2, is being explored in a phase I clinical trial for the treatment of AML, other myeloid malignancies, solid tumors, and gliomas. ..
  6. Stein E. IDH2 inhibition in AML: Finally progress?. Best Pract Res Clin Haematol. 2015;28:112-5 pubmed publisher
    ..Notably, many cases of acute myeloid leukemia (AML) have mutations in R172 and R140. The impact of these mutations and early results of inhibiting mutant IDH2 with the reversible inhibitor AG-221 are discussed in this review. ..
  7. Epstein Peterson Z, Devlin S, Stein E, Estey E, Tallman M. Widespread use of measurable residual disease in acute myeloid leukemia practice. Leuk Res. 2018;67:92-98 pubmed publisher
    ..Standardization of assays, adoption of requisite technology, and dissemination of data about the value of MRD use would likely increase usage of MRD in the care of patients with AML. ..
  8. Stein E, Walter R, Erba H, Fathi A, Advani A, Lancet J, et al. A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33 positive acute myeloid leukemia (AML). Blood. 2017;: pubmed publisher
    ..6 weeks for platelets (?100,000/µL). Vadastuximab talirine demonstrates activity and a tolerable safety profile as a single agent in patients with AML. The recommended monotherapy dose is 40 µg/kg...